Ignite Creation Date:
2025-12-24 @ 9:09 PM
Ignite Modification Date:
2025-12-27 @ 8:42 PM
Study NCT ID:
NCT06952504
Status:
RECRUITING
Last Update Posted:
2025-12-24
First Post:
2025-04-23
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
Sponsor:
Merck Sharp & Dohme LLC
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2025-05-22
Start Date Type:
ACTUAL
Primary Completion Date:
2032-05-24
Primary Completion Date Type:
ESTIMATED
Completion Date:
2032-05-24
Completion Date Type:
ESTIMATED
First Submit Date:
2025-04-23
First Submit QC Date:
None
Study First Post Date:
2025-05-01
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-12-23
Last Update Post Date:
2025-12-24
Last Update Post Date Type:
ACTUAL